SwePub
Tyck till om SwePub Sök här!
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:1474 547X "

Sökning: L773:1474 547X

  • Resultat 31-40 av 914
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
31.
  •  
32.
  •  
33.
  •  
34.
  • Asplund, Kjell, et al. (författare)
  • The need to revise the Helsinki Declaration
  • 2017
  • Ingår i: The Lancet. - : ELSEVIER SCIENCE INC. - 0140-6736 .- 1474-547X. ; 389:10075, s. 1190-1191
  • Tidskriftsartikel (refereegranskat)
  •  
35.
  •  
36.
  •  
37.
  • Audeh, M. William, et al. (författare)
  • Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
  • 2010
  • Ingår i: The Lancet. - 1474-547X. ; 376:9737, s. 245-251
  • Tidskriftsartikel (refereegranskat)abstract
    • Background Olaparib is a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor that induces synthetic lethality in homozygous BRCA-deficient cells. We aimed to assess the efficacy and safety of olaparib for treatment of advanced ovarian cancer in patients with BRCA1 or BRCA2 mutations. Methods In this international, multicentre, phase 2 study, we enrolled two sequential cohorts of women (aged >= 18 years) with confirmed genetic BRCA1 or BRCA2 mutations, and recurrent, measurable disease. The study was undertaken in 12 centres in Australia, Germany, Spain, Sweden, and the USA. The first cohort (n=33) was given continuous oral olaparib at the maximum tolerated dose of 400 mg twice daily, and the second cohort (n=24) was given continuous oral olaparib at 100 mg twice daily. The primary efficacy endpoint was objective response rate (ORR). This study is registered with ClinicalTrials.gov, number NCT00494442. Findings Patients had been given a median of three (range 1-16) previous chemotherapy regimens. ORR was 11 (33%) of 33 patients (95% CI 20-51) in the cohort assigned to olaparib 400 mg twice daily, and three (13%) of 24 (4-31) in the cohort assigned to 100 mg twice daily. In patients given olaparib 400 mg twice daily, the most frequent causally related adverse events were nausea (grade 1 or 2,14 [42%]; grade 3 or 4, two [6%]), fatigue (grade 1 or 2, ten [30%]; grade 3 or 4, one [3%]), and anaemia (grade 1 or two, five [15%1; grade 3 or 4, one [3%]). The most frequent causally related adverse events in the cohort given 100 mg twice daily were nausea (grade 1 or 2, seven [29%]; grade 3 or 4, two [8%]) and fatigue (grade 1 or 2, nine [38%]; none grade 3 or 4). Interpretation Findings from this phase 2 study provide positive proof of concept of the efficacy and tolerability of genetically targeted treatment with olaparib in BRCA-mutated advanced ovarian cancer.
  •  
38.
  • Auer, MK, et al. (författare)
  • Congenital adrenal hyperplasia
  • 2023
  • Ingår i: Lancet (London, England). - 1474-547X. ; 401:10372, s. 227-244
  • Tidskriftsartikel (refereegranskat)
  •  
39.
  • Augestad, KM, et al. (författare)
  • A Littre bleed
  • 2012
  • Ingår i: Lancet (London, England). - 1474-547X. ; 380:9846, s. 1030-1030
  • Tidskriftsartikel (refereegranskat)
  •  
40.
  • Augustsson, Katarina, et al. (författare)
  • Dietary heterocyclic amines and cancer of the colon, rectum, bladder, and kidney : a population-based study
  • 1999
  • Ingår i: The Lancet. - 0140-6736 .- 1474-547X. ; 353:9154, s. 703-707
  • Tidskriftsartikel (refereegranskat)abstract
    • Background Heterocyclic amines formed in cooked meat and fish are carcinogenic in animal models and form DNA adducts in human beings. We undertook a study to assess whether these substances are related to the risks of cancer in the large bowel and urinary tract. Methods In a population-based case-control study, cases were identified from the Swedish cancer registry. Controls were randomly selected from the population register. Information on intake of various foods and was assessed by questionnaire, with photographs of foods cooked at various temperatures. We measured the content of heterocyclic amines in foods cooked under these conditions. Findings Information was retrieved from 553 controls, 352 cases of colon cancer, 249 cases of rectal cancer, 273 cases of bladder cancer, and 138 cases of kidney cancer. The response rate was 80% for controls and 70% for cases. The estimated daily median intake of heterocyclic amines was 77 ng for controls, and 66 ng, 63 ng, 96 ng, and 84 ng for cases with cancer of the colon, rectum, bladder, and kidney, respectively. The relative risk for the intake of heterocyclic amines (highest vs lowest quintile) was 0.6 (95% CI 0.4-1.0) for colon cancer, 0.7 (0.4-1.1) for rectal cancer, 1.2 (0.7-2.1) for bladder cancer, and 1.0 (0.5-1.9) for kidney cancer. Seven cases, but no controls, had an estimated daily intake of heterocyclic amines above 1900 ng. Interpretation Intake of heterocyclic amines, within the usual dietary range in this study population, is unlikely to increase the incidence of cancer in the colon, rectum, bladder, or kidney. For daily intakes above 1900 ng, our data are consistent with human carcinogenicity, but the precision was extremely low.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 31-40 av 914
Typ av publikation
tidskriftsartikel (871)
forskningsöversikt (33)
konferensbidrag (7)
annan publikation (3)
Typ av innehåll
refereegranskat (756)
övrigt vetenskapligt/konstnärligt (155)
populärvet., debatt m.m. (3)
Författare/redaktör
Gupta, R. (40)
Malekzadeh, R (39)
Dandona, L (37)
Naghavi, M (37)
Farzadfar, F (36)
Dandona, R (35)
visa fler...
Fischer, F (35)
Larsson, Anders (34)
Jonas, JB (33)
Monasta, L (33)
Nangia, V (31)
Remuzzi, G (31)
Shiri, R (31)
Alvis-Guzman, N (30)
Koyanagi, A (30)
Majeed, A (30)
Mohammed, S (30)
Mokdad, AH (30)
Shibuya, K (30)
Venketasubramanian, ... (30)
Bikbov, B (29)
Hafezi-Nejad, N (29)
Kosen, S (29)
Lozano, R (29)
Topor-Madry, R (29)
Hamidi, S (28)
Meretoja, A (28)
Moradi-Lakeh, M (28)
Perico, N (28)
Ronfani, L (28)
Karch, A (27)
Leigh, J (27)
Sepanlou, SG (27)
Singh, JA (27)
Abd-Allah, F (26)
Alam, K (26)
Kabir, Z (26)
Lalloo, R (26)
Mckee, M (26)
Mendoza, W (26)
Pesudovs, K (26)
Basu, S (25)
Bhutta, ZA (25)
Brenner, H (25)
Hay, SI (25)
Jha, V (25)
Kumar, GA (25)
Lopez, AD (25)
Radfar, A (25)
Rawaf, S (25)
visa färre...
Lärosäte
Karolinska Institutet (483)
Uppsala universitet (202)
Lunds universitet (163)
Umeå universitet (122)
Göteborgs universitet (111)
Linköpings universitet (54)
visa fler...
Högskolan Dalarna (45)
Stockholms universitet (29)
Örebro universitet (25)
Mittuniversitetet (15)
Chalmers tekniska högskola (14)
Södertörns högskola (7)
Högskolan i Skövde (7)
Jönköping University (5)
Karlstads universitet (5)
Kungliga Tekniska Högskolan (3)
Luleå tekniska universitet (3)
Mälardalens universitet (3)
Högskolan i Borås (3)
Handelshögskolan i Stockholm (2)
Linnéuniversitetet (2)
Sophiahemmet Högskola (2)
Högskolan i Gävle (1)
Malmö universitet (1)
Blekinge Tekniska Högskola (1)
Marie Cederschiöld högskola (1)
Sveriges Lantbruksuniversitet (1)
Röda Korsets Högskola (1)
visa färre...
Språk
Engelska (914)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (441)
Samhällsvetenskap (21)
Naturvetenskap (5)
Teknik (1)
Lantbruksvetenskap (1)
Humaniora (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy